Several parameters (i.e., androgen-receptor status, gene expression, growth patterns) are responsible for the heterogeneity of PCa and determine the choice between active surveillance for the more indolent disease, curative treatment (prostatectomy or radiotherapy) for localized disease, or systemic therapy for advanced cancer [1, 3]. Here, AR is linked to posterior cortical atrophy.